1. Home
  2. COGT vs NX Comparison

COGT vs NX Comparison

Compare COGT & NX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • NX
  • Stock Information
  • Founded
  • COGT 2014
  • NX 1927
  • Country
  • COGT United States
  • NX United States
  • Employees
  • COGT 205
  • NX N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • NX Metal Fabrications
  • Sector
  • COGT Health Care
  • NX Industrials
  • Exchange
  • COGT Nasdaq
  • NX Nasdaq
  • Market Cap
  • COGT 822.0M
  • NX 824.7M
  • IPO Year
  • COGT 2018
  • NX N/A
  • Fundamental
  • Price
  • COGT $7.23
  • NX $18.23
  • Analyst Decision
  • COGT Buy
  • NX Strong Buy
  • Analyst Count
  • COGT 6
  • NX 1
  • Target Price
  • COGT $15.20
  • NX $38.00
  • AVG Volume (30 Days)
  • COGT 2.1M
  • NX 515.6K
  • Earning Date
  • COGT 08-05-2025
  • NX 06-05-2025
  • Dividend Yield
  • COGT N/A
  • NX 1.75%
  • EPS Growth
  • COGT N/A
  • NX N/A
  • EPS
  • COGT N/A
  • NX 0.39
  • Revenue
  • COGT N/A
  • NX $1,625,028,000.00
  • Revenue This Year
  • COGT N/A
  • NX $49.00
  • Revenue Next Year
  • COGT N/A
  • NX $2.99
  • P/E Ratio
  • COGT N/A
  • NX $46.63
  • Revenue Growth
  • COGT N/A
  • NX 47.66
  • 52 Week Low
  • COGT $3.72
  • NX $15.30
  • 52 Week High
  • COGT $12.61
  • NX $34.97
  • Technical
  • Relative Strength Index (RSI)
  • COGT 65.40
  • NX 49.22
  • Support Level
  • COGT $6.88
  • NX $18.48
  • Resistance Level
  • COGT $7.83
  • NX $19.93
  • Average True Range (ATR)
  • COGT 0.56
  • NX 0.92
  • MACD
  • COGT 0.09
  • NX -0.01
  • Stochastic Oscillator
  • COGT 78.17
  • NX 37.26

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About NX Quanex Building Products Corporation

Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its three operating segments are North American Fenestration being the key revenue driver, European Fenestration, and North American Cabinet Components. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: